Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The phase 3 study “A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of IBI363 Versus Docetaxel…” tests a new treatment option for advanced squamous non small cell lung cancer after standard drugs stop working. The trial matters because it targets a large, high-need group and could reshape second or later line care in lung cancer.
The main treatment is IBI363, an infused antibody drug designed to boost the immune system against cancer. It is compared with docetaxel, a long-standing chemotherapy that serves as the current standard benchmark in this setting.
The study is interventional and randomized, with patients assigned 1:1 to IBI363 or docetaxel. It is open label, so doctors and patients know which drug is given, and the core goal is to see if IBI363 improves outcomes versus usual chemotherapy.
The trial first appeared on the registry on 31 Aug 2025, marking the formal start of public tracking and enrollment. The latest update was filed on 06 Mar 2026, signaling that the protocol and status are current and that the study is still in the recruiting phase.
For investors, the update reinforces that Takeda and partners Fortvita Biologics (USA) Inc. and Innovent Biologics are pushing a late stage lung cancer asset toward a potential value inflection point. Positive data versus docetaxel could lift sentiment for all three companies and add pressure on rivals in the crowded lung cancer field, while weak results could weigh on shares.
While timelines and data readouts are still ahead, the fact that a large, global phase 3 program is underway supports the strategic focus on immune based lung cancer therapies. The study remains active and updated, with further details available on the ClinicalTrials portal.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
